Product
Hemay005
Aliases
60mg Hemay005, Hemay005 60 mg, Hemay005 tablet, Hemay005 treatment group (3 other aliases)
9 clinical trials
7 indications
Indication
Ankylosing SpondylitisIndication
Behcet SyndromeIndication
Hemay005Indication
Atopic DermatitisIndication
PsoriasisIndication
HealthyIndication
Ulcerative ColitisClinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study on the Efficacy and Safety of hemay005 Tablets in the Treatment of Active Ankylosing SpondylitisStatus: Completed, Estimated PCD: 2023-08-18
Clinical trial
A Phase III Clinical Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseStatus: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
A Phase II Study to Evaluate the Efficacy and Safety of Hemay005 Tablet in Adult With Moderate to Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2024-01-24
Clinical trial
Clinical Study of Safety, Tolerability, and Pharmacokinetics of Hemay005 Tablets in Single and Multiple Doses in Healthy SubjectsStatus: Completed, Estimated PCD: 2021-08-01
Clinical trial
A Phase Ⅲ Multicenter, Randomized, Double-blind, Placebo-controlled To Assess Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque PsoriasisStatus: Completed, Estimated PCD: 2022-10-25
Clinical trial
A Phase I, Single-arm, Open-label, Ethnobridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Oral Doses of Hemay005 Tablets in Healthy Caucasian Adult VolunteersStatus: Completed, Estimated PCD: 2023-08-08
Clinical trial
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Mild, Moderate Liver Impairment and Normal Liver Function After a Single Oral AdministrationStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo Parallel Controlled Clinical Study on the Effecacy and Safety of Low-High Dosing Regimens of Hemay005 in Patients With Moderate to Severe Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Mild and Moderate Renal Impairment and Normal Renal Function After a Single Oral AdministrationStatus: Not yet recruiting, Estimated PCD: 2024-12-01